Sharon Cave-Adens
Psychiatric/Mental Health · Philadelphia, PANPI 1093089567
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,690 and has fallen 71.2% since, to $486 in 2025.
Across 76 payments — averaging $50.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$658
- Novo Nordisk$609
- Braeburn Inc.$448
- AbbVie$376
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$304
- Johnson & Johnson$250
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,864100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 9 | $658 |
| Novo Nordisk | 11 | $609 |
| Braeburn Inc. | 8 | $448 |
| AbbVie | 6 | $376 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $304 |
| Johnson & Johnson | 2 | $250 |
| Biohaven Pharmaceuticals, Inc. | 5 | $197 |
| Idorsia Pharmaceuticals US Inc | 3 | $144 |
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Amgen | 1 | $109 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $108 |
| Abbott | 1 | $108 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $75 |
| Lilly USA, LLC | 4 | $66 |
| Viiv Healthcare Company | 2 | $55 |
| Cipher Pharmaceuticals US LLC | 1 | $55 |
| Indivior Inc. | 3 | $48 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Novartis | 2 | $30 |
| Lundbeck LLC | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Alkermes, Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$483
- BRIXADI$374
- RYBELSUS$349
- XARELTO$250
- CAPLYTA$241
- VRAYLAR$236
- DUPIXENT$122
- SHINGRIX$117
- Repatha$109
- NURTEC ODT$108
- CARDIOMEMS$108
- QUVIVIQ$108
How this compares
$3,864 in reported general payments places this provider in the 85th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
See all psychiatric/mental health providers in Pennsylvania →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 11 | $293 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Philadelphia
- Andrew RenziPhiladelphia$13K
- Clement JohnPhiladelphia$13K
- Rena LindenPhiladelphia$9K
- Gordon ZeisPhiladelphia$8K
- Kimberly GarciaAllentown$573K
- Cortney SmithWashington$227K
- Britney KeplerPittsburgh$158K
- Kirstyn KamegBethel Park$136K
- Anna DipietroDowningtown$131K
- Deena MasciocchiLanghorne$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.